STAT3 and Miyoshi myopathy: Pharmacological inhibition of the JAK–STAT3 pathway results in STAT3 phosphorylation in MM cell lines, an upregulation of CD38 expression in primary MM patients, and an increase in daratumumab antibody-mediated cellular cytotoxicity against MM cell lines [83].